Search Results - "Morden, JP"

Abstract P3-13-01: Withdrawn by Robertson, JFR, Morden, JP, Dowsett, M, Smith, I, Bliss, JM

“…This abstract was withdrawn by the authors…”
Get full text

Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method by Latimer, Nicholas R, Abrams, KR, Lambert, PC, Crowther, MJ, Wailoo, AJ, Morden, JP, Akehurst, RL, Campbell, MJ

“…Estimates of the overall survival benefit of new cancer treatments are often confounded by treatment switching in randomised controlled trials (RCTs) – whereby…”
Get full text

Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study by Latimer, Nicholas R, Abrams, Keith R, Lambert, Paul C, Morden, James P, Crowther, Michael J

“…When patients randomised to the control group of a randomised controlled trial are allowed to switch onto the experimental treatment, intention-to-treat…”
Get full text

Adjusting Survival Time Estimates to Account for Treatment Switching in Randomized Controlled Trials—an Economic Evaluation Context: Methods, Limitations, and Recommendations by Latimer, Nicholas R., Abrams, Keith R., Lambert, Paul C., Crowther, Michael J., Wailoo, Allan J., Morden, James P., Akehurst, Ron L., Campbell, Michael J.

“…Background. Treatment switching commonly occurs in clinical trials of novel interventions in the advanced or metastatic cancer setting. However, methods to…”
Get full text

Abstract GS1-03: Peri-operative aromatase inhibitor treatment in determining or predicting longterm outcome in early breast cancer – The POETIC Trial (CRUK/07/015) by Robertson, JFR, Dowsett, M, Bliss, JM, Morden, JP, Wilcox, M, Evans, A, Holcombe, C, Horgan, K, Kirwan, C, Mallon, E, Sibbering, M, Skene, A, Vidya, R, Cheang, M, Banerji, J, Kilburn, L, Dodson, A, Smith, I

“…Background Experimental evidence (Fisher et al, 1989) & a small clinical trial (IMPACT) respectively suggested peri-operative endocrine therapy (ET) may…”
Get full text

Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study by Morden, James P, Lambert, Paul C, Latimer, Nicholas, Abrams, Keith R, Wailoo, Allan J

“…We investigate methods used to analyse the results of clinical trials with survival outcomes in which some patients switch from their allocated treatment to…”
Get full text

The Application and Feasibility of Using Routine Data Sources for Long-term Cancer Clinical Trial Follow-up by Bhattacharya, I.S., Morden, J.P., Griffin, C., Snowdon, C., Brannan, R., Bliss, J.M., Kilburn, L.

Get full text

Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019) by Cameron, D, Barrett-Lee, P, Canney, P, Banerji, J, Bartlett, J, Bloomfield, D, Bowden, S, Brunt, M, Earl, H, Ellis, P, Fletcher, M, Morden, JP, Robinson, A, Sergenson, N, Stein, R, Velikova, G, Verrill, M, Wardley, A, Coleman, R, Bliss, JM

“…Introduction: TACT2, a multicentre randomized phase III trial in patients with node +ve or high risk node -ve invasive EBC with E-CMF as control (Poole NEJM…”
Get full text